Canget BioTekpharma LLC

Expand page content
Year 2020:
Special News
  • Canget BioTekpharma Announces Exclusive Worldwide Agreement with Pinot Bio to Develop Antibody-Drug Conjugates

    - New Product Will Deliver High Payload to Drug Resistant Cancers

    Buffalo, NY— September 15, 2021 — Today, Canget BioTekpharma and PinotBio announced the signing of an agreement to develop new products that combine technologies from both companies to improve outcomes for patients with resistant cancers.

    Canget small molecule platform overcomes multiple mechanisms of drug resistance - “Canget platform compounds have demonstrated the ability to eliminate cancer and address multiple forms of drug resistance,” said Canget BioTekpharma CEO John J Seman. “Combining Canget technology with PinotBio expertise in the development of antibody drug conjugates will deliver increased amounts of antitumor drugs with enhanced targeting of treatment resistant cancers”.

    Antibody Drug Conjugates (ADC) - Antibody-drug conjugates are one of the fastest growing categories of anticancer drugs in the current pharmaceutical industry. The approach comprises a monoclonal antibody (mAb) conjugated to a small molecule via an appropriate chemical linker that is directed toward a target antigen expressed on the cancer cell surface. This technology will reduce systemic exposure of the small molecule drug and therefore, avoiding potential systemic toxicity. “Our ADC technology is highly targeted and can carry a powerful amount of drug directly to the surface of the targeted cancer cells.” said PinotBio CEO Doo Young Jung.

    International Opportunity - Under the terms of the agreement, PinotBio will develop one or more new ADC products with Canget drug platform technology, conduct all pre-clinical and clinical studies, and address all regulatory requirements for market approval. Canget BioTekpharma will be scientifically supportive in this process and providenon-GMP and GMP materials for development and commercialization.

    Canget BioTekpharma LLC (Canget) - Canget BioTekpharma LLC (701 Ellicott Street, Buffalo, NY 14203 USA) is a biopharma company, spun out from Roswell Park Comprehensive Cancer Center (

    PinotBio Inc. - PinotBio Inc. (, 156 Gwanggvoro, Youngtonggu, Suwon – Republic of Korea) is a venture-backed Korea-based biotechnology company focused on the discovery and development of novel oncology therapies for a wide range of tumors.
Media News
  • Canget CEO John J. Seman has participated in the Oncology Investor Conference (March 31 – April 1, 2020, New York City). Due to the coronavirus issue, this investment event has been conducted virtually. Through this Oncology Investor meeting, Canget has developed valuable partners including a cancer biomarker testing company, which will facilitate the future FL118 biomarker-driven clinical trial. John’s Canget Technology slide deck presentation used in this meeting by CEO John Seman is in the link below.
    or click the following and watch the video directly:
  • Pancreatic Cancer Action Network ( officer Valerie Holzherr recently informed Dr. Fengzhi Li at Roswell Park Comprehensive Cancer Center for supporting his FL118 pancreatic cancer translational project using the 2020 PanCAN Translational Research Grant.
  • Canget Board members including the Acting CEO John S. Seman, CSO, Fengzhi Li, Board members, Martin Casstevans (business affaire expert) and Brian Pettit (human resources expert) have recently gathered at Buffalo for discussing a list of urgent events that need to be moved forward. This includes partnership status and out licensing/sublicensing status update, outside investment status update, top north CEO recruitment status update, IND filing timeline update and Series A Funding planning.
  • In early 2020, Canget has finished additional outside investment from individual USA investors.
Year 2019:
Year 2018:
Year 2017:
Year 2016:
Year 2015:
Year 2014:
Year 2013:
Year 2012:
Year 2020
Year 2019
Year 2018
Year 2017
Year 2016
Year 2015
Year 2014
Year 2013
Year 2012
Year 2011

Canget BioTekpharma Company Copyright. All rights reserved.